Injecting human growth hormone as a performance-enhancing drug-perspectives from the United Kingdom

Journal of Substance Use

Volumn 14, Issue 5, 2009, Pages 267-288

  Evans Brown, Michael ^a   Mcveigh, Jim ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

20th century history; Acromegaly; Anabolic steroids; Body image; Causality; Drug adulteration counterfeits; Growth hormone; Harm reduction; Needle and Syringe Programmes; Observational research; Performance enhancing drugs; United Kingdom

Indexed keywords

HUMAN GROWTH HORMONE;

CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; GROWTH HORMONE DEFICIENCY; HUMAN; MULTIPLE DRUG ABUSE; POPULATION RESEARCH; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TURNER SYNDROME; UNITED KINGDOM;

EID: 73549125563     PISSN: 14659891     EISSN: 14759942     Source Type: Journal    
DOI: 10.3109/14659890903224383     Document Type: Review

References (128)

1. Adams, B. B., (2004). Co-occurrence does not imply association. International Journal of Dermatology, 43(9), 699-700.
2. Anderson, I. B., Kim, S. Y., Dyer, J. E., Burkhardt, C. B., Iknoian, J. C., Walsh, M. J., et al. (2006). Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Annals of Emergency Medicine, 47(2), 177-183.
3. Ayuk, J., & Sheppard, M. C. (2006). Growth hormone and its disorders. Postgraduate Medical Journal, 82(963), 24-30.
4. Ayuk, J., & Sheppard, M. C. (2008). Does acromegaly enhance mortality? Reviews in Endocrine & Metabolic Disorders, 9(1), 33-39.
5. Baker, J. S., Graham, M. R., & Davies, B. (2006). Steroid and prescription medicine abuse in the health and fitness community: A regional study. European Journal of Internal Medicine, 17(7), 479-484.
6. Beck, J. C., McGarry, E. E., Dyrenfurth, I., & Venning, E. H. (1957). Metabolic effects of human and monkey growth hormone in man. Science, 125(3253), 884-885.
7. Belay, E. D., & Schonberger, L. B. (2005). The public health impact of prion diseases. Annual Review of Public Health, 26, 191-212.
8. Blakeslee, S. (1987). Supply of growth hormone brings hope for new uses. Retrieved August 24, 2009 from http://www.nytimes.com/1987/02/10/science/supply- of-growth-hormone-brings-hope-for-new-uses.html
9. Bolding, G., Sherr, L., & Elford, J. (2002). Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction, 97(2), 195-203.
10. British Medical Association & Royal Pharmaceutical Society of Great Britain. (2008). British national formulary (No 56). London: BMJ Group and RPS Publishing.
11. Brown, P. S. (1984). Anterior pituitary hormones: Definition, measurement and use. In M. J. Parnham & J. Bruinvels (Eds.), Discoveries in pharmacology, volume 2: Haemodynamics, hormones and inflammation. Oxford, UK: Elsevier Science Publications.
12. Burton, C. (1996). Anabolic steroid use among the gym population in Clwyd. Pharmaceutical Journal, 256, 557-559.
13. Centres for Disease Control (CDC). (1985). Fatal degenerative neurologic disease in patients who received pituitary-derived human growth hormone. MMWR. Morbidity and Mortality Weekly Report, 34(24), 359-360, 365-366.
14. Centers for Disease Control (CDC). (1990). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR. Morbidity and Mortality Weekly Report, 39(47), 861-863.
15. Chin, M. Y., Kreutzer, R. A., & Dyer, J. E. (1999). Acute poisoning from gamma-hydroxybutyrate in California. Western Journal of Medicine, 56(4), 380-384.
16. Cohen, J., Collins, R., Darkes, J., & Gwartney, D. (2007). A league of their own: Demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. Journal of the International Society of Sports Nutrition, 4(1). Retrieved August 24, 2009 from http://www.jissn.com/content/4/1/12
17. Crampin, A. C., Lamagni, T. L., Hope, V. D., Newham, J. A., Lewis, K. M., Parry, J. V., et al., (1998). The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Epidemiology and Infection, 121(2), 381-386.
18. Criminal Justice Act 2003 (c. 44). (2003). London: Her Majesty's Stationery Office.
19. Crist, D. M., Peake, G. T., Egan, P. A., & Waters, D. L. (1988). Body composition response to exogenous GH during training in highly conditioned adults. Journal of Applied Physiology, 65(2), 579-584.
20. Cronin, M. J. (1997). Pioneering recombinant growth hormone manufacturing: Pounds produced per mile of height. Journal of Pediatrics, 131(1 Pt 2), 85-87.
21. Daughaday, W. H., Hall, K., Raben, M. S., Salmon, W. D. Jr., van den Brande, J. L., van Wyk, J. J. (1972). Somatomedin: Proposed designation for sulphation factor. Nature, 235(5333), 107.
22. Dawkins, R. (2006). The selfish gene. Oxford, UK: Oxford University Press.
23. Dawson, R. T. (2001). Drugs in sport - the role of the physician. Journal of Endocrinology, 170(1), 55-61.
24. Deyssig, R., & Frisch, H. (1993). Self-administration of cadaveric growth hormone in power athletes. Lancet, 341(8847), 768-769.
25. Drazen, J. M. (2003). Inappropriate advertising of dietary supplements. New England Journal of Medicine, 348(9), 777-778.
26. Duchaine, D. (1989). The underground steroid handbook II (Incorporating material from the original Underground Steroid Handbook, Ultimate Muscle Mass, and the USH Updates #1-10.). Venice, CA: HLR Technical Books.
27. Ellis, M. (1988, December 15). Chemist struck off roll for steroid deal with bodybuilders; Halil Ozdemir. The Times (London, England), pp. N/A.
28. Evans, H. M., & Long, J. A. (1921). The effect of the anterior lobe administered intraperitoneally upon growth, maturity and oestrus cycles of the rat. The Anatomical Record, 21(1), 62-63.
29. Evans, N. A. (1997). Local complications of self administered anabolic steroid injections. British Journal of Sports Medicine, 31 (1), 54-58.
30. Evans-Brown, M., & McVeigh, J. (2009). Anabolic steroid use in the general population of the United Kingdom. In V. Møller, P. Dimeo, & M. McNamee (Eds.), Elite sport, doping, and public health (pp. 75-97). Odense, Denmark: University of Southern Denmark Press.
31. Flodh, H. (1986). Human growth hormone produced with recombinant DNA technology: Development and production. Acta Paediatrica Scandinavica Supplement, 325, 1-8.
32. Flodh, H. (1987). Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem). Acta Paediatrica Scandinavica Supplement, 331, 1-4.
33. Food and Drug Administration. (1985a). Human growth hormone distribution discontinued. FDA Drug Bulletin, 15(2), 17-18.
34. Food and Drug Administration. (1985b). Genetically engineered human growth hormone approved. FDA Drug Bulletin, 15(4), 38-39.
35. Food and Drug Administration. (2004). FDA and the US Attorney for the Western District of Texas announce guilty plea in drug counterfeiting case. Retrieved August 24, 2009 from http://www.fda.gov/bbs/topics/news/2004/ NEW01036.html
36. Fryklund, L. (1987). Production of authentic recombinant somatropin. Acta Paediatrica Scandinavica Supplement, 331, 5-8. (Pubitemid 17051467)
37. Garner, S. T., & Miles, N. A. (1985). Abuse of anabolic steroids. British Medical Journal, 291(6497), 741.
38. Genentech. (1985). FDA approves Genentech's drug to treat children's growth disorder. Retrieved 24 August 2009 from http://www.gene.com/gene/news/ press-releases/display.do?method=detail&id=4235
39. Gibbs, C. J., Joy, A., Heffner, R., Franko, M., Miyazaki, M., Asher, D. M., et al. (1985). Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. New England Journal of Medicine, 313(12), 734-738.
40. Gibney, J., Healy, M-L., Sönksen, P. H. (2007). The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocrine Reviews, 28(6), 603-624.
41. Gilliver, D. (2007, 22 October). Getting through to the body beautifuls. Drink & Drugs News, p. 8.
42. Giustina, A., & Veldhuis, J. D. (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews, 9(6), 717-797.
43. Goetsch, E. (1916). The influence of pituitary feeding upon growth and sexual development. An experimental study. Bulletin of Johns Hopkins Hospital, 27, 29-50.
44. Goldman, B., Bush, P. J., & Klatz, R. (1984). Death in the locker room. South Bend, IN: Icarus Press.
45. Gonzalez, A., & Nutt, D. J. (2005). Gamma hydroxy butyrate abuse and dependency. Journal of Psychopharmacology, 19(2), 195-204.
46. Grace, F., Baker, J., & Davies, B. (2001). Anabolic androgenic steroid use in recreational gym users: A regional sample of the Mid-Glamorgan area. Journal of Substance Use, 6(3), 189-195.
47. Graham, M., Ryan, P., Baker, J. S., Davies, B., Thomas, N-E., Cooper, S. M., et al. (2009). Counterfeiting in performance and image enhancing drugs. Drug Testing and Analysis, 1, 135-142.
48. Grogan, S. (2008). Body image: Understanding body dissatisfaction in men, women and children (2nd ed.). Hove, East Sussex: Routledge.
49. Hansard, H. L. (1996, 7 May). vol.572, part 87.
50. Health Protection Agency Centre for Infections. (2006). The UK Collaborative Group for HIV and STI Surveillance. A complex picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. London: Health Protection Agency.
51. Health Protection Agency Centre for Infections. (2008). Hepatitis C in the UK 2008. London: Health Protection Agency.
52. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, Communicable Disease Surveillance Centre Northern Ireland Northern Ireland, & Centre for Research on Drugs &
53. Health Behaviour, London School of Hygiene & Tropical Medicine. (2008). Shooting up: Infections among injecting drug users in the United Kingdom 2007. London: Health Protection Agency.
54. HM Government. (1971). Misuse of Drugs Act 1971. (c.38). London: Her Majesty's Stationery Office.
55. Holl, R. W., Hartman, M. L., Veldhuis, J. D., Taylor, W. M., & Thorner, M. O. (1991). Thirty-second sampling of plasma growth hormone in man: Correlation with sleep stages. Journal of Clinical Endocrinology and Metabolism, 72(4), 854-861.
56. Holt, R. I., & Sönksen, P. H. (2008). Growth hormone, IGF-I and insulin and their abuse in sport. British Journal of Pharmacology, 154(3), 542-556.
57. Ikkos, D., Luft, R., & Gemzell, C. A. (1958). The effect of human growth hormone in man. Lancet, 271(7023), 720-721.
58. Kaplan, S. A., & Cohen, P. (2007). The somatomedin hypothesis 2007: 50 years later. Journal of Clinical Endocrinology and Metabolism, 92(12), 4529-4535.
59. Kaplan, S. L., Underwood, L. E., August, G. P., Bell, J. J., Blethen, S. L., Blizzard, R. M., et al. (1986). Clinical studies with recombinant-DNA- derived methionyl human growth hormone in growth hormone deficient children. Lancet, 327(8483), 697-700.
60. Klatz, R., & Kahn, C. (1998). Grow young with HGH. New York: HarperCollins.
61. Koch, T. K., Berg, B. O., De Armond, S. J., & Gravina, R. F. (1985). Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. New England Journal of Medicine, 313(12), 731-733.
62. Korkia, P., & Stimson, G. V. (1993). Anabolic steroid use in Great Britain: An exploratory investigation. A report to the department of health, the Welsh office and the chief scientist office, Scottish home and health department. London: Her Majesty's Stationery Office.
63. Korner, A., Randle, P., Young, F. G., Crooke, A. C., Fletcher, R. F., Sammons, H. G., et al. (1959). The effectiveness in man of human growth hormone. Lancet, 273(7062), 7-12.
64. Larance, B., Degenhard, L., Copeland, J., & Dillon, P. (2008). Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug and Alcohol Review, 27(6), 679-686.
65. Lenehan, P., & McVeigh, J. (1997). Anabolic steroids. A guide for professionals. Liverpool: The Drugs and Sport Information Service, University of Liverpool.
66. Lenehan, P., McVeigh, J., & Bellis, M. A. (1996). A study of anabolic steroid use in the North West of England. Journal of Performance Enhancing Drugs, 1(2), 57-70.
67. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L., & Butler, A. (2001). The somatomedin hypothesis: 2001. Endocrine Reviews, 22(1), 53-74.
68. Lewis, R. A., Klein, R., & Wilkins, L. (1950). The effect of pituitary growth hormone in dwarfism with osseous retardation and hypoglycemia and in a cretin treated with thyroid. Journal of Clinical Investigation, 29(4), 460-464.
69. Li, C. H., & Evans, H. M. (1944). The isolation of pituitary growth hormone. Science, 99(2566), 183-184.
70. Li, C. H., Evans, H. M., & Simpson, M. E. (1945). Isolation and properties of the anterior hypophyseal growth hormone. Journal of Biological Chemistry, 159(2), 353-366.
71. Li, C. H., Evans, H. M., & Simpson, M. E. (1948). Crystallization of hypophyseal growth hormone. Science, 108(2814), 624-625.
72. Li, C. H., & Papkoff, H. (1956). Product and properties of growth hormone from human and monkey pituitary glands. Science, 124(3235), 1293-1294.
73. Liu, H., Bravata, D., Olkin, I., Friedlander, A., Liu, V., Roberts, B., et al., (2007). Systematic review: The effects of growth hormone on athletic performance. Annals of Internal Medicine, 148(10), 747-758.
74. Llewellyn, W. (2009). Anabolics (9th ed.). Jupiter, FL: Body of Science.
75. Luft, R., Ikkos, D., Gemzell, C. A., & Olivecrona, H. (1958). Effect of human growth hormone in hypophysectomised diabetic subjects. Lancet, 271(7023), 721-722.
76. Magnavita, N., Teofili, L., & Leone, G. (1996). Hodgkin's lymphoma in a cyclist treated with growth hormone. American Journal of Hematology, 52(1), 65-66.
77. McKillop, P. (1987). Drug abuse in body builders in the West of Scotland. Scottish Medical Journal, 32(2), 39-41.
78. McVeigh, J., Beynon, C., & Bellis, M. A. (2003). New challenges for agency based syringe exchange schemes: Analysis of 11 years of data (1991 to 2001) in Merseyside and Cheshire, UK. International Journal of Drug Policy, 14(5-6), 353-357.
79. McVeigh, J., Chandler, M., Beynon, C., Evans-Brown, M. J., & Bellis, M. A. (2007, May 13-17). The injectors that harm reduction forgot. Poster session presented at the 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
80. Milio, N. (1981). Promoting health through public policy. Philadelphia, PA: F. A. Davis Company.
81. Milner, R. D. (1985). Growth hormone 1985. British Medical Journal, 291(6509), 1593-1594.
82. Milner, R. D., Russell-Fraser, T., Brook, C. G., Cotes, P. M., Farquhar, J. W., Parkin, J. W., et al. (1979). Experience with human growth hormone in Great Britain: The report of the MRC Working Party. Clinical Endocrinology, 11(1), 15-38.
83. Mishkind, M. E., Rodin, J., Silberstein, L. R., & Striegel-Moore, R. H. (1986). The embodiment of masculinity: Cultural, psychological, and behavioral dimensions. American Behavioral Scientist, 29(5), 545-562.
84. Moerman, D. (2002). Meaning, medicine and the 'placebo effect'. Cambridge: Cambridge University Press.
85. Monaghan, L. F. (2001). Bodybuilding, drugs and risk. London: Routledge.
86. National Institute for Clinical Excellence.(2002). Guidance on the use of human growth hormone (somatropin) in children with growth failure (Technology Appraisal No. 42). National Institute for Clinical Excellence: London, United Kingdom.
87. National Institute for Clinical Excellence. (2003). Human growth hormone (somatropin) in adults with growth hormone deficiency (Technology Appraisal 64). National Institute for Clinical Excellence: London.
88. Nelson, A. E., & Ho, K. K. (2007). Abuse of growth hormone by athletes. Nature Clinical Practice Endocrinology & Metabolism, 3(3), 198-199.
89. Newsweek.( 1996, September 16). Attention: Aging men. Testosterone and other hormone treatments offer new hope for staying youthful, sexy and strong. Newsweek. Retrieved August 24, 2009 from http://www.newsweek.com/id/102829
90. Olshansky, S. J., & Perls, T. T. (2008). New developments in the illegal provision of growth hormone for 'antiaging' and bodybuilding. Journal of the American Medical Association, 299(23), 2792-2794.
91. Parkinson, A. B., & Evans, N. A. (2006). Anabolic androgenic steroids: A survey of 500 users. Medicine and Science in Sports and Exercise, 38(4), 644-651.
92. Pates, R., & Barry, C. (1996). Steroid use in Cardiff: A problem for whom? Journal of Performance Enhancing Drugs, 1(3), 92-97.
93. Perls, T. T. (2004). Anti-aging quackery: Human growth hormone and tricks of the trade - more dangerous than ever. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 59(7), 682-691.
94. Perls, T. T. (2006). Hope drives antiaging hype. Cleveland Clinic Journal of Medicine, 73(12), 1039-1040, 1044.
95. Peterson, F. C., & Brooks, C. L. (2000). The species specificity of growth hormone requires the cooperative interaction of two motifs. FEBS Letters, 472(2-3), 276-282.
96. Powell-Jackson, J., Weller, R. O., Kennedy, P., Preece, M. A., Whitcombe, E. M., & Newsom-Davis, J. (1985). Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet, 2(8449), 244-246.
97. Raben, M. S. (1958). Treatment of a pituitary dwarf with human growth hormone. Journal of Clinical Endocrinology and Metabolism, 18(8), 901-903.
98. Robertson, T. B. (1916). Experimental studies on growth. III. The influence of the anterior lobe of the pituitary body upon the growth of the white mouse. Journal of Biological Chemistry, 24(3), 385-396.
99. Rogers, E. M. (2003). Diffusion of innovations. New York: Free Press.
100. Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., et al. (1990). Effects of human growth hormone in men over 60 years old. New England Journal of Medicine, 323(1), 1-6.
101. Schäfer, E. A. (1908). The functions of the pituitary body. Proceedings of the Royal Society of London. Series B, 81(550), 442-468.
102. Sein Anand, J., Chodorowski, Z., & Wisniewski, M. (2005). Multifactorial hypoglycaemic coma in female bodybuilder. Przeglad lekarski, 62(6), 520-521.
103. Serono, Inc. (2001). Serono statement regarding counterfeit Serostim® . Retrieved August 24, 2009 from http:// www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173895.htm
104. Shorr, E., Carter, A. C., Kennedy, B. J., & Smith, R. W. (1953). Metabolic studies on the effects of crystalline growth hormone (somatotropin) in man. Transactions of the Association of American Physicians, 66, 114-126.
105. Simpson, H., Savine, R., Sönksen, P., Bengtsson, B. A., Carlsson, L., Christiansen, J. S., et al., (2002). Growth hormone replacement therapy for adults: Into the new millennium. Growth Hormone & IGF Research, 12(1), 1-33.
106. Smith, P. E., & Smith, I. P. (1922). The effect of intraperitoneal injection of fresh anterior lobe substance in hypophysectomized tadpoles. Anatomical Record, 23(1), 38-39.
107. Sutton, J., & Lazarus, L. (1976). Growth hormone in exercise: Comparison of physiological and pharmacological stimuli. Journal of Applied Physiology, 41(4), 523-527.
108. Takahashi, Y., Kipnis, D. M., & Daughaday, W. H. (1968). Growth hormone secretion during sleep. Journal of Clinical Investigation, 47(9), 2079-2090.
109. Tattersall, R. (1996). A history of growth hormone. Hormone Research, 46(4-5), 236-247.
110. Taylor, W. (1991). Macho medicine: A history of the steroid epidemic. London: McFarland & Company.
111. The Misuse of Drugs Act 1971 (Modification) Order 1996. (1996). SI 1300. London: Her Majesty's Stationery Office.
112. The Misuse of Drugs (Amendment) Regulations 1996. (1996). SI 1597. London: Her Majesty's Stationery Office.
113. The Misuse of Drugs Regulations 2001. (2001). SI 3998. London: Her Majesty's Stationery Office.
114. Tober, R. (2005). The many faces of growth hormone. Body of Science, 1(3), 24-31. Retrieved August 24, 2009 from http://www.bodyofscience.com/files/ counterfeit-summer2005.pdf
115. Tober, R. (2007). Chinese growth hormone. Body of Science, 2(2), 28-35. Retrieved August 24, 2009 from http://www.bodyofscience.com/files/ChineseGH.pdf
116. Van Cauter, E., Latta, F., Nedeltcheva, A., Spiegel, K., Leproult, R., Vandenbril, C., et al., (2004). Reciprocal interactions between the growth hormone axis and sleep. Growth Hormone & IGF Research, 14(Suppl A), S10-S17.
117. Van Cauter, E., Plat, L., Scharf, M. B., Leproult, R., Cespedes, S., L'Hermite-Balériaux, M., et al., (1997). Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. Journal of Clinical Investigation, 100(3), 745-753.
118. Vance, M. L. (2003). Can growth hormone prevent aging? New England Journal of Medicine, 348(9), 779-780.
119. Veldhuis, J. D. (2003). A tripeptidyl ensemble perspective of interactive control of growth hormone secretion. Hormone Research, 60(Suppl. 1), 86-101.
120. Velloso, C. P. (2008). Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology, 154(3), 557-568.
121. Wilhelmi, A. E., Fishman, J. B., & Russell, J. A. (1948). A new product of crystalline anterior pituitary growth hormone. Journal of Biological Chemistry, 176(2), 735-745.
122. World Health Organization (WHO). (1986). Ottawa charter for health promotion. Retrieved August 24, 2009 from http://www.who.int/healthpromotion/ conferences/previous/ottawa/en/
123. World Health Organization. (2003). Substandard and counterfeit medicines. Retrieved August 24, 2009 from http://www.who.int/mediacentre/factsheets/2003/ fs275/en/
124. World Health Organization. (n.d.) (a). What are substandard drugs? Retrieved from August 24, 2009 http://www.who.int/medicines/services/ counterfeit/faqs/06/en/index.html
125. World Health Organization. (n.d.) (b). How does WHO define a counterfeit drug (medicine)? Retrieved August 24, 2009 from http://www.who.int/medicines/ services/counterfeit/faqs/03/en/index.html
126. World Health Organization. (n.d.) (c). Retrieved August 24, 2009 from http://www.who.int/medicines/services/ counterfeit/faqs/15/en/index.html
127. Yesalis, C. E., Wright, J. E., & Bahrke, M. (1989). Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids. Sports Medicine, 8(3), 129-138.
128. Young, J., & Anwar, A. (2007). Strong diabetes. British Journal of Sports Medicine, 41(5), 335-336.